Using reverse bioengineering for target compounds, we develop AI-powered microbial production platforms that enable faster development, lower costs, and reliable commercial-scale supply. From pathway design to scale-up, we help bring novel compounds with differentiated pharmacological profiles to market faster.
From target definition to commercial production, explore Metaorganic's four-step development protocol.
Share the pharmacological profile and performance requirements you are targeting. We define the scope clearly and design the optimal development path.
We use AI-driven microbial reverse engineering to design the most efficient production pathway for your target compound.
We translate pathway design into a scalable production recipe optimized by Metabolism AI.
We establish a stable production system for reliable commercial-scale supply.
See how Metaorganic's next-generation platform outperforms conventional cell factory workflows.
The competitive advantages clients gain through Metaorganic's ODM service.
AI simulation and our proprietary library dramatically reduce trial and error. Compared with conventional workflows, development costs can be reduced by up to 75% while timelines are accelerated more than fourfold.
AI-powered reverse engineering enables the development of entirely new target compounds, including those that are rare in nature or previously unavailable.
Beyond lab-scale discovery, we enable reliable commercial-scale production through metabolic pathway recipes optimized for scale-up.
By activating natural gene expression mechanisms instead of relying on engineered edits such as CRISPR, we help produce compounds with lower side-effect risk and stronger biological activity and pharmacological efficacy.